BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8202719)

  • 1. Platinum compounds in cervical and endometrial cancers: focus on carboplatin.
    Muggia FM; Muderspach L
    Semin Oncol; 1994 Apr; 21(2 Suppl 2):35-41; quiz 42, 58. PubMed ID: 8202719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers.
    Muggia FM
    Semin Oncol; 2004 Dec; 31(6 Suppl 14):17-24. PubMed ID: 15726530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carcinoma of the uterine cervix: current status and future directions.
    Thigpen T; Vance RB; Khansur T
    Semin Oncol; 1994 Apr; 21(2 Suppl 2):43-54; quiz 55, 58. PubMed ID: 8202720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers.
    Monk BJ; Alberts DS; Burger RA; Fanta PT; Hallum AV; Hatch KD; Salmon SE
    Gynecol Oncol; 1998 Nov; 71(2):308-12. PubMed ID: 9826477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gynecologic malignancies.
    Schilder RJ; Scher RM; Young RC
    Cancer Chemother Biol Response Modif; 1993; 14():530-56. PubMed ID: 8312118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The future role of carboplatin.
    Ruckdeschel JC
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):114-8. PubMed ID: 7992063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer.
    Hotta K; Matsuo K; Ueoka H; Kiura K; Tabata M; Tanimoto M
    J Clin Oncol; 2004 Oct; 22(19):3852-9. PubMed ID: 15326195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gynecological malignancies.
    Schaebler DL; Schilder RJ; Young RC
    Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gynecologic malignancies.
    Young RC
    Cancer Chemother Biol Response Modif; 1987; 9():303-37. PubMed ID: 2856338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase.
    Deng HB; Adikari M; Parekh HK; Simpkins H
    Cancer Chemother Pharmacol; 2004 Oct; 54(4):301-7. PubMed ID: 15138708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review).
    Boulikas T; Vougiouka M
    Oncol Rep; 2004 Mar; 11(3):559-95. PubMed ID: 14767508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer.
    Moore KN; Herzog TJ; Lewin S; Giuntoli RL; Armstrong DK; Rocconi RP; Spannuth WA; Gold MA
    Gynecol Oncol; 2007 May; 105(2):299-303. PubMed ID: 17303230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
    Jiang J; Liang X; Zhou X; Huang R; Chu Z
    Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
    Ozols RF
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer.
    Dubay RA; Rose PG; O'Malley DM; Shalodi AD; Ludin A; Selim MA
    Gynecol Oncol; 2004 Jul; 94(1):121-4. PubMed ID: 15262129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined-modality therapy of locally advanced cervical cancer.
    Rose PG
    J Clin Oncol; 2003 May; 21(10 Suppl):211s-217s. PubMed ID: 12743137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemotherapy in endometrial carcinoma: overview of randomised trials.
    Hogberg T
    Clin Oncol (R Coll Radiol); 2008 Aug; 20(6):463-9. PubMed ID: 18467080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.
    Duska LR; Berkowitz R; Matulonis U; Muto M; Goodman A; McIntyre JF; Klein A; Atkinson T; Seiden MV; Campos S
    Gynecol Oncol; 2005 Jan; 96(1):198-203. PubMed ID: 15589601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
    Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
    Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.